Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Odronextamab · REGN-1979

Bispecific antibody · Kills target cells, directed at CD20 (MS4A1) and CD3 (CD3E) · developed by Regeneron Pharmaceuticals

Phase 2/3 Most advanced trial
1 Registered trials

What is Odronextamab?

Odronextamab is a bispecific monoclonal antibody that binds CD20 on B-cell lymphoma cells and CD3 on T cells, cross-linking them to trigger cytotoxic T-lymphocyte responses. It is studied in B-cell non-Hodgkin lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-1979
Drug type
Bispecific antibody
Targets
CD20 (MS4A1), CD3 (CD3E)
Mechanism
Kills target cells, directed at CD20 (MS4A1) and CD3 (CD3E)
Pathways
cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Regeneron Pharmaceuticals
In trials of
ADCT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
8R5CM46UIO

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05991388 Phase 2/3 B-cell Non Hodgkin Lymphoma Recruiting ADCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Non Hodgkin Lymphoma

Other drugs acting on MS4A1 / CD3E

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved AZD5492 Phase 1/2 CT-95 Phase 1 Foralumab Phase 2 Gocatamig Phase 1/2 Imvotamab Phase 1/2 Mipletamig Phase 1 MK-1045 Phase 2/3 TAK-186 Phase 1/2 TL011 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.